Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2006

View Archived Issues

MK-0518 combination therapy yields HIV RNA reduction at 24 weeks

Novel antiarthritic compounds described in recent patents

Trimeris and Roche report on new potent fusion inhibitors with potential for once-weekly dosing

Insulin-stimulating properties of Hon-Chi reported

Targeting the pronociceptive action of CCK-8 for diabetes-induced peripheral sensitization

Novel treatment strategies for respiratory disorders claimed in recent patents

Ono patent discloses new compounds for treating HIV infection

ADA and EASD issue consensus statement on metformin treatment

Preliminary analysis from MEDAL program for Arcoxia

NeuroSearch to acquire Carlsson Research

CK-1827452 studied for oral administration

VivaGel studied for safety in men

Zileuton i.v. improves FEV1 in asthma patients

TPM-02/Insulin successfully delivers insulin across skin

Epigenetic targeting in psychopharmacology - a new avenue of research

KC-706 set to advance into phase II for inflammatory conditions

MGCD-0103 studied in phase II trial for relapsed or refractory Hodgkin's disease

NuPathe licenses LAD long acting delivery technology from U. of Pennsylvania

Dendreon submits sections of rolling BLA for Provenge

BrainStorm Cell Therapeutics to target stroke with adult stem cell technology

PXD-101 studied in aggressive B-cell lymphoma

GSK and ChemoCentryx establish strategic alliance in inflammatory disorders

Guanfacine extended release NDA filed for ADHD

ImmunoVaccine Technologies to use PADRE for vaccines

GlaxoSmithKline's Relenza approved in 15 E.U. countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...